Skip to main content
. 2019 Jun 18;14:4475–4489. doi: 10.2147/IJN.S208225

Figure 3.

Figure 3

Viability of HUVECs exposed with NPs from CCK-8 assay. The * indicates significant differences between the control group and the nanoparticles treatment group (*: P<0.05, **: P<0.01).